For research use only. Not for therapeutic Use.
SRS11-92, a Ferrostatin-1 (Fer-1) analogue, is a potent ferroptosis inhibitor. SRS11-92 inhibits ferroptotic cell death induced by Erastin in HT-1080 human fibrosarcoma cells (EC50=6 nM)[1].
SRS11-92 fully protects oligodendrocytes (OLs) from cystine deprivation when tested at 100 nM. SRS11-92 rescues primary human fibroblasts from death induced by frataxin knock-down[2].
SRS11-92, used at 500 nM, is efficacious in protecting human and mouse cellular models of Friedreich ataxia (FRDA) treated with ferric ammonium citrate (FAC) and an inhibitor of glutathione synthesis (BSO), whereas caspase-3 inhibitors fail to show significant biological activity[2].
| Catalog Number | I045555 |
| CAS Number | 1467047-25-1 |
| Synonyms | ethyl 3-(benzylamino)-4-(cyclohexylamino)benzoate |
| Molecular Formula | C22H28N2O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H28N2O2/c1-2-26-22(25)18-13-14-20(24-19-11-7-4-8-12-19)21(15-18)23-16-17-9-5-3-6-10-17/h3,5-6,9-10,13-15,19,23-24H,2,4,7-8,11-12,16H2,1H3 |
| InChIKey | VHQAJFNLPQULSV-UHFFFAOYSA-N |
| SMILES | CCOC(=O)C1=CC(=C(C=C1)NC2CCCCC2)NCC3=CC=CC=C3 |
| Reference | [1]. Skouta R, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc. 2014;136(12):4551-4556. [2]. Cotticelli MG, et al. Ferroptosis as a Novel Therapeutic Target for Friedreich’s Ataxia. J Pharmacol Exp Ther. 2019;369(1):47-54. |
